Oxford Nanopore CEO’s $1 Billion Sales Goal Sends Stock Soaring
Oxford Nanopore Technologies Plc plans to focus on the most lucrative opportunities in gene sequencing, including quality control for mRNA vaccines, as it moves closer to break even in an...
By Ashleigh Furlong · Bloomberg
Oxford Nanopore Technologies Plc plans to focus on the most lucrative opportunities in gene sequencing, including quality control for mRNA vaccines, as it moves closer to break even in an increasingly competitive market.